Top Story

Ibrutinib combination confers significant benefit in relapsed CLL

May 30, 2015

Read the Perspective from Stefan Barta, MD

CHICAGO – The addition of ibrutinib to bendamustine and rituximab conferred an 80% reduction in the risk for progression or death in patients with previously treated chronic lymphocytic leukemia, according to the interim results of a phase 3 study presented at the ASCO Annual Meeting.

“CLL is an incurable disease, and every single patient will relapse,” Asher Alban Chanan-Khan, MD, professor of medicine and chair of hematology and oncology at the Mayo Clinic in Jacksonville, Florida, told HemOnc Today. “For the first time, we have developed a drug which is improving the chances of going into remission. This can deliver significant responses without significant toxicity.”

Saad Usmani, MD Meeting News Coverage

Daratumumab appears safe, effective in heavily pretreated multiple myeloma

May 30, 2015
CHICAGO – The monoclonal antibody daratumumab yielded durable single-agent activity in patients with heavily treated multiple myeloma, according to the results of…
Meeting News Coverage

Nivolumab yields superior OS in NSCLC compared with docetaxel

May 30, 2015
CHICAGO — Nivolumab conferred a 3-month median OS advantage in patients with non-squamous non–small cell lung cancer who progressed on platinum-based doublet…
Meeting News Coverage

Nivolumab shows promise for advanced hepatocellular carcinoma

May 29, 2015
CHICAGO — Nivolumab appeared safe and effective for the treatment of patients with advanced hepatocellular carcinoma, according to interim study results presented…
Tanguy Seiwert, MD Meeting News Coverage

Pembrolizumab demonstrates 'remarkable' efficacy in advanced head and neck cancers

May 29, 2015
CHICAGO — The anti–PD-1 antibody pembrolizumab demonstrated strong activity in patients with recurrent or metastatic head and neck squamous cell carcinoma…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Updates in prostate cancer treatment options

VIDEO: Updates in prostate cancer treatment options

May 5, 2015
Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey, discusses various forms of prostate cancer…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan
morganatic-roan